echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Green Leaf Pharmaceuticals: China's first compound liposome sylipeer innovation is about to enter clinical

    Green Leaf Pharmaceuticals: China's first compound liposome sylipeer innovation is about to enter clinical

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    On June 11, Green Leaf Pharmaceuticals announced that its clinical application for its self-developed anti-tumor innovation, the Iliticonfluene lipid injection (LY01616), has been accepted by the Drug Review Center of the State Drug Administration of China and is about to enter clinical trialsThis is the first declared clinical compound lipid drug, its preparation technology requirements are high, the process is difficult, showing that the green leaf pharmaceutical group in the field of compound lipid research and development and manufacturing to obtain a new breakthroughThe combined chemotherapy of Ilythikang combined fluorouretic is one of the first options for advanced colorectal cancerLY01616 is an innovative compound lipid containing both Iliticon and fluoroxeliac for the treatment of advanced colorectal cancer, which is not currently available worldwideCombined chemotherapy has become the standard solution for clinical treatment of tumors at home and abroadCompared with single-drug chemotherapy, combined chemotherapy can play a synergistic role by using different mechanisms of drug, thus reducing the occurrence of drug resistance and improving the effect of chemotherapyHowever, the efficacy of combined chemotherapy is closely related to the proportion of the drugs used, and a specific proportion of synergies helps to achieve the best outcomeFor traditional combined chemotherapy, due to the nature of the drug itself, different metabolic pathways in the body and other reasons, it is difficult to maintain the original synergy ratio after the combination drug into the body, affecting the actual efficacyLY01616 is precisely to solve this clinical problem, it will be combined drugs in a specific synergetic proportion package in the same lipid body, compared with the traditional combined chemotherapy methods have a number of advantages, including: 1) to carry drugs in a specific proportion, delivery of drugs to target tissue, better achieve the synergetic effect of combined chemotherapy;
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.